Key Points
- Director Colin Walsh purchased 85,000 Attovia Therapeutics shares at an average price of $21, investing $1.785 million. He later bought an additional 500,000 shares for $8.5 million at $17 per share.
- Walsh also sold 105,807 shares for approximately $2.25 million at an average price of $21.28, making his recent insider activity include both substantial purchases and a sale.
- BlackRock increased its Attovia stake by 23.4% in the second quarter, owning 164,358 shares valued at about $317,000 in its latest SEC filing.
Attovia Therapeutics, Inc. (NASDAQ:ATTO - Get Free Report) Director Colin Walsh acquired 85,000 shares of the company's stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $21.00 per share, with a total value of $1,785,000.00. Following the purchase, the director directly owned 85,000 shares in the company, valued at approximately $1,785,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Colin Walsh also recently made the following trade(s):
- On Wednesday, August 5th, Colin Walsh sold 105,807 shares of Attovia Therapeutics stock. The shares were sold at an average price of $21.28, for a total transaction of $2,251,572.96.
- On Thursday, August 6th, Colin Walsh bought 500,000 shares of Attovia Therapeutics stock. The shares were acquired at an average price of $17.00 per share, for a total transaction of $8,500,000.00.
Attovia Therapeutics Price Performance
NASDAQ ATTO opened at $19.86 on Friday. Attovia Therapeutics, Inc. has a 1-year low of $16.15 and a 1-year high of $22.79.
Hedge Funds Weigh In On Attovia Therapeutics
An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. grew its stake in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO - Free Report) by 23.4% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 164,358 shares of the company's stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.'s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.
Attovia Therapeutics Company Profile
(
Get Free Report)
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company's research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
